Alopecia areata

Disease ID:1200
Name:Alopecia areata
Associated with:0 targets
0 immuno-relevant targets
2 immuno-relevant ligands
Synonyms
circumscribed alopecia
Description
A hypersensitivity reaction type II disease causing loss of head and body hair, initially causing bald spots.
Database Links
Disease Ontology: DOID:986

Targets

No target related data available for Alopecia areata

Ligands

Ligand Approved Immuno References Clinical comments
tralokinumab
Clinical Use: Tralokinumab reached Phase 3 clinical trials for uncontrolled asthma, and atopic dermatitis, and Phase 2 for alopecia areata. Click here to link to ClinicalTrials.gov's listing of Phase III tralokinumab trials. In addition, Phase 2 trials are investigating tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca have discontinued tralokinumab development as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1].
Immuno Disease Comments: Phase 2 clinical candidate for alopecia areata (see NCT02684097).
PF-06651600
Clinical Use: PF-06651600 has completed Phase 1clinical trial for inflammatory bowel disease (see NCT02309827). Phase 1 studies in rheumatoid arthritis, ulcerative colitis and alopecia areata are underway.
Immuno Disease Comments: Phase 1 clinical candidate for AA (NCT02974868)

References

Show »

1. Adams B. Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018. fiercebiotech.com, https://www.fiercebiotech.com/biotech/sanofi-ditches-il4-il13-antibody-drug-lung-scarring-disease